For biopharmaceutical companies, gene therapies are an economic challenge. They are expensive to make yet the diseases the treat are rare, so manufacturers tend to charge a lot for them to generate ...
Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that ...
Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...
Induced pluripotent stem cells, the workhorse of many regenerative medicine projects, start out as differentiated cells that are reprogrammed to pluripotent stem cells by exposure to a complex set of ...
WALTHAM, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced four poster presentations at the ...
Effective process development for viral vector-based medicines is paramount for optimized process efficiency, robustness, scalability, and product quality. Well-designed processes streamline ...
Saratoga, CA (June 6, 2023) – Vector Flow, the digital transformation leader in physical security automation, is proud to announce a new partnership with Nedap, a Dutch multinational technology ...